Urogen Pharma (NASDAQ:URGN) Insider Sells $350,100.00 in Stock

Posted by Brian Himes on Jun 24th, 2026

Urogen Pharma (NASDAQ:URGN – Get Free Report) insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $35.01, for a total value of $350,100.00. Following the sale, the insider directly owned 129,763 shares of the company’s stock, valued at $4,543,002.63. This represents a 7.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Schoenberg also recently made the following trade(s):

On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60.

Urogen Pharma Trading Up 1.4%

NASDAQ URGN traded up $0.50 during trading on Wednesday, reaching $35.65. The company’s stock had a trading volume of 64,154 shares, compared to its average volume of 783,415. The firm has a 50 day moving average price of $27.67 and a 200 day moving average price of $23.12. Urogen Pharma has a 12 month low of $12.73 and a 12 month high of $36.08. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -12.99 and a beta of 1.59.

Urogen Pharma (NASDAQ:URGN – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to the consensus estimate of $44.83 million. On average, equities analysts forecast that Urogen Pharma will post -0.98 EPS for the current fiscal year.

Institutional Trading of Urogen Pharma

Several institutional investors have recently modified their holdings of the business. Osaic Holdings Inc. grew its position in shares of Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after acquiring an additional 486 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after acquiring an additional 3,125 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after acquiring an additional 5,571 shares during the last quarter. Finally, Nebula Research & Development LLC acquired a new stake in shares of Urogen Pharma during the second quarter worth $162,000. Institutional investors own 91.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on URGN. HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of Urogen Pharma in a research report on Wednesday, June 3rd. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a report on Tuesday, June 2nd. D. Boral Capital reissued a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a report on Tuesday, March 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $39.50.

Read Our Latest Stock Report on URGN

About Urogen Pharma

(Get Free Report)

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.